These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 14577920

  • 1. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model.
    Ahn WS, Bae SM, Kim TY, Kim TG, Lee JM, Namkoong SE, Kim CK, Sin JI.
    Hum Gene Ther; 2003 Oct 10; 14(15):1389-99. PubMed ID: 14577920
    [Abstract] [Full Text] [Related]

  • 2. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
    Jin HS, Park EK, Lee JM, NamKoong SE, Kim DG, Lee YJ, Jun HJ, Han BD, Bae SM, Ahn WS.
    Gynecol Oncol; 2005 May 10; 97(2):559-67. PubMed ID: 15863160
    [Abstract] [Full Text] [Related]

  • 3. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY, Myoung HJ, Kim JH, Moon IS, Kim TG, Ahn WS, Sin JI.
    Cancer Res; 2002 Dec 15; 62(24):7234-40. PubMed ID: 12499264
    [Abstract] [Full Text] [Related]

  • 4. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.
    Clin Cancer Res; 2008 Jan 01; 14(1):178-87. PubMed ID: 18172269
    [Abstract] [Full Text] [Related]

  • 5. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.
    Kim MS, Sin JI.
    Immunology; 2005 Oct 01; 116(2):255-66. PubMed ID: 16162274
    [Abstract] [Full Text] [Related]

  • 6. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity against human papillomavirus 16-associated tumor.
    Park EK, Kim YW, Lee JM, NamKoong SE, Kim DG, Chun HJ, Han BD, Bae SM, Jin HS, Sin JI, Ahn WS.
    Cancer Res Treat; 2005 Feb 01; 37(1):63-70. PubMed ID: 19956512
    [Abstract] [Full Text] [Related]

  • 7. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model.
    Kim TG, Kim CH, Won EH, Bae SM, Ahn WS, Park JB, Sin JI.
    Immunology; 2004 May 01; 112(1):117-25. PubMed ID: 15096191
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.
    Bae SH, Park YJ, Park JB, Choi YS, Kim MS, Sin JI.
    Clin Cancer Res; 2007 Jan 01; 13(1):341-9. PubMed ID: 17200373
    [Abstract] [Full Text] [Related]

  • 9. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
    Nguyen CT, Hong SH, Sin JI, Vu HV, Jeong K, Cho KO, Uematsu S, Akira S, Lee SE, Rhee JH.
    Vaccine; 2013 Aug 20; 31(37):3879-87. PubMed ID: 23831323
    [Abstract] [Full Text] [Related]

  • 10. Photodynamic therapy with recombinant adenovirus AdmIL-12 enhances anti-tumour therapy efficacy in human papillomavirus 16 (E6/E7) infected tumour model.
    Park EK, Bae SM, Kwak SY, Lee SJ, Kim YW, Han CH, Cho HJ, Kim KT, Kim YJ, Kim HJ, Ahn WS.
    Immunology; 2008 Aug 20; 124(4):461-8. PubMed ID: 18397271
    [Abstract] [Full Text] [Related]

  • 11. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH, Jin HT, Park SH, Youn JI, Sung YC.
    Vaccine; 2009 Sep 25; 27(42):5906-12. PubMed ID: 19651174
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response.
    Tan J, Yang NS, Turner JG, Niu GL, Maassab HF, Sun J, Herlocher ML, Chang AE, Yu H.
    Cancer Gene Ther; 1999 Sep 25; 6(4):331-9. PubMed ID: 10419051
    [Abstract] [Full Text] [Related]

  • 13. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.
    Ji H, Wang TL, Chen CH, Pai SI, Hung CF, Lin KY, Kurman RJ, Pardoll DM, Wu TC.
    Hum Gene Ther; 1999 Nov 20; 10(17):2727-40. PubMed ID: 10584920
    [Abstract] [Full Text] [Related]

  • 14. Cytotoxic T lymphocytes elicited by dendritic cell-targeted delivery of human papillomavirus type-16 E6/E7 fusion gene exert lethal effects on CaSki cells.
    Wu XM, Liu X, Jiao QF, Fu SY, Bu YQ, Song FZ, Yi FP.
    Asian Pac J Cancer Prev; 2014 Nov 20; 15(6):2447-51. PubMed ID: 24761845
    [Abstract] [Full Text] [Related]

  • 15. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.
    Lamikanra A, Pan ZK, Isaacs SN, Wu TC, Paterson Y.
    J Virol; 2001 Oct 20; 75(20):9654-64. PubMed ID: 11559797
    [Abstract] [Full Text] [Related]

  • 16. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
    Lee DW, Anderson ME, Wu S, Lee JH.
    Arch Otolaryngol Head Neck Surg; 2008 Dec 20; 134(12):1316-23. PubMed ID: 19075129
    [Abstract] [Full Text] [Related]

  • 17. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
    Riezebos-Brilman A, Walczak M, Regts J, Rots MG, Kamps G, Dontje B, Haisma HY, Wilschut J, Daemen T.
    Gene Ther; 2007 Dec 20; 14(24):1695-704. PubMed ID: 17928874
    [Abstract] [Full Text] [Related]

  • 18. Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression.
    Sin JI.
    Immunology; 2009 Sep 20; 128(1 Suppl):e707-17. PubMed ID: 19740332
    [Abstract] [Full Text] [Related]

  • 19. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants.
    Ohlschläger P, Quetting M, Alvarez G, Dürst M, Gissmann L, Kaufmann AM.
    Int J Cancer; 2009 Jul 01; 125(1):189-98. PubMed ID: 19358269
    [Abstract] [Full Text] [Related]

  • 20. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
    Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Jayaprabhu S, Pecorelli S, Parham GP, Cannon MJ.
    Clin Cancer Res; 2001 Mar 01; 7(3 Suppl):804s-810s. PubMed ID: 11300476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.